Yazar "Baştürk, A." seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim Yok
    Öğe
    CHEMOTHERAPY IMPROVED COAGULATION DISORDER IN A PATIENT WITH MULTIPLE MYELOMA
    (PERGAMON-ELSEVIER SCIENCE LTD, 2015) Fidan, K.; Kutlucan, A.; Dağlı, M.; Baştürk, A.; Sözen, Mehmet; Abuşoğlu, Sedat; Kutlucan, L.
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    EVALUATION OF BONE MINERAL DENSITY AND PARAMETERS RELATED TO BONE METABOLISM IN HEMOPHILIC PATIENTS
    (PERGAMON-ELSEVIER SCIENCE LTD, 2017) Dağlı, M.; Kutlucan, A.; Abuşoğlu, Sedat; Baştürk, A.; Sözen, Mehmet; Kutlucan, L.; Ünlü, Ali
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    IRON DEFICIENCY ANEMIA INDUCED THROMBOCYTOPENIA: A CASE REPORT
    (PERGAMON-ELSEVIER SCIENCE LTD, 2015) Baştürk, A.; Ayhan, M.; Akıncı, S.; Hacıbekiroğlu, T.; Güney, T.; Kutlucan, A.; Dilek, I.
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    MANTLE CELL LYMPHOMA PRESENTING WITH ACUTE APPENDICITIS
    (PERGAMON-ELSEVIER SCIENCE LTD, 2015) Baştürk, A.; Eren, S.; Akıncı, S.; Hacıbekiroğlu, T.; Güney, T.; Kutlucan, A.; Ecirli, S.
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    Prognostic significance of flow cytometry findings in Turkish adult acute leukemia patients
    (VERDUCI PUBLISHER, 2015) Baştürk, A.; Akıncı, S.; Hacıbekiroğlu, T.; Güney, T.; Kutlucan, A.; Ceran, F.; Akalın, S. D.
    OBJECTIVE: Several factors are known to affect prognosis of acute leukemia such as age, high leukocyte count, cytogenetic abnormality, performance status and recurrent leukemia. We aimed to investigate the association between cell surface markers and prognostic determinants such as recurrence at 6 and 12 months and survival at 6, 12 and 18 months in acute leukemia patients. PATIENTS AND METHODS: A total of 142 patients, 101 with acute myeloid leukemia (AML) and 41 with B-cell acute lymphoblastic leukemia (B-ALL) were included. The effects of surface markers on survival and recurrence rates were evaluated retrospectively. RESULTS: In AML patients, CD5+ and CD34+ immunophenotypes and in ALL patients cCD22+, CD34+ and CD49f + CD19+ immunophenotypes were positive prognostic indicators. In AML patients CD7 expression, and in ALL patients CD5+, CD7+ and CD117+ immunophenotypes and >90% CD45 expression were negative prognostic indicators. CONCLUSIONS: This study demonstrates that flow cytometry, a common diagnostic tool in acute leukemia, may also have prognostic value in acute leukemia in the future.